Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
CREAM
**How to use this medication?** For topical use only. Apply thin and evenly to the affected area two or three times daily. To ensure complete healing, and depending on the indications, the treatment should be continued for about two weeks after the disappearance of the symptoms. Usual treatment duration: White spots: 1–3 weeks Erythrasma: 2–4 weeks Candida vulvitis and candida balanitis: 1–2 weeks Other fungal infections: 3–4 weeks To prevent reoccurrence of fungal infections of the feet, treatment should be continued for about 2 weeks beyond the disappearance of all symptoms. After washing, the feet should be thoroughly dried (spaces between the toes) before application of the cream. You should notify your physician if there is no improvement after the recommended duration of treatment. Follow all directions given to you by your doctor and pharmacist carefully. They may differ from the information contained in this leaflet. If you do not understand the instructions on the label, ask your doctor or pharmacist for help.
TOPICAL
Medical Information
**What is this medication used for?** Covee is used for fungal skin infections such as ringworm, athlete’s foot, jock itch, white spots, fungal infections of skinfolds and erythrasma. Covee Cream can also be used for female fungal infections of the vaginal area, It can also be used in males where inflammation is present in the penis caused by yeast fungi ( _candida vulvitis and candida balanitis_). Covee contains clotrimazole, an antifungal agent belongs to the group of medicine called imidazoles. It works by inhibiting the biosynthesis of ergosterol, a component for cell wall production; hence altering the permeability of cell membrane of fungi.
**When should you not take this medicine?** Do not use Covee if you have known hypersensitivity to any ingredients in this medicine.
D01AC01
clotrimazole
Manufacturer Information
APEX PHARMA MARKETING PTE. LTD.
XEPA-SOUL PATTINSON (M) SDN BHD
Active Ingredients
Documents
Patient Information Leaflets
Enclosure (iv)-Proposed PIL_Covee Cr 300921.pdf
Approved: December 27, 2021